All In Biotech

Company

Shionogi

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

8

3 still marketed

Novel approvals

6

Approvals since 2021

2

Originals and new uses

Phase 3 trials

33

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Xocova approved NovelMay 29, 2026
  • Radicava Ors approved Priority reviewOrphanMay 12, 2022
  • Fetroja new use Priority reviewSep 25, 2020
  • Fetroja approved NovelPriority reviewNov 14, 2019
  • Radicava approved NovelOrphanMay 5, 2017
  • Ulesfia approved NovelApr 9, 2009
  • Doribax approved NovelOct 12, 2007
  • Rybix Odt approved May 5, 2005

Drugs in development (3)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • BPN14770zatolmilastPhase 34 trials

    Tetra Discovery Partners · Fragile X Syndrome, Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder

  • RedasemtideRedasemtide trifluoroacetate, S-005151Phase 21 trial

    Shionogi · Acute Ischemic Stroke

  • SASS-001Phase 21 trial

    Shionogi · Sleep Apnea

Recruiting Phase 3 trials

Largest first.

Marketed drugs (3)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.